CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sangamo Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sangamo Therapeutics Inc
501 Canal Blvd.
Phone: (510) 970-6000p:510 970-6000 RICHMOND, CA  94084  United States Ticker: SGMOSGMO
Business Summary
Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board H. StewartParker 69 6/1/2017 6/17/2014
President, Chief Executive Officer, Director Alexander D.Macrae 62 6/14/2016 6/1/2016
Chief Financial Officer, Senior Vice President PrathyushaDuraibabu 46 6/1/2021 6/14/2019
7 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
TxCell SA Allee de la Nertiere Les Cardoulines Valbonne France
Ceregene, Inc. 9381 Judicial Dr., Ste. 130 San Diego CA United States

Business Names
Business Name
CG Acquisition Sub, Inc.
Gendaq Limited
Sangamo Biosciences, Inc.
Sangamo Therapeutics France S.A.S.
SGMO
Txcell SA

General Information
Number of Employees: 183 (As of 12/31/2024)
Outstanding Shares: 237,599,090 (As of 5/14/2025)
Shareholders: 50
Stock Exchange: NASD
Federal Tax Id: 680359556
Fax Number: (302) 655-5049
Email Address: info@sangamo.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, July 7, 2025